They certainly may achieve submission, but I am certainly not filled with confidence of the quality of the application. They haven’t managed to attract and employ a suitable European pharmaceutical executive in a timely manner, despite having had 18 months to develop and execute a ROW development plan/team.
US-based executives with limited experience with the EMA, complemented by some Consultants doesn’t scream “big leagues” to me.
I am not sure Acadia’s own board is filled with confidence either, given the recent high level, involuntary management separations.
One person’s opinion, but I can’t help but feel we’ve given a “major league” asset to a “minor league” team.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)